AbbVie takes pivekimab pivotal
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
